6 days ago
Vera Therapeutics (VERA) Receives a Buy from Raymond James
Raymond James analyst Ryan Deschner reiterated a Buy rating on Vera Therapeutics (VERA – Research Report) today and set a price target of $73.00. The company's shares opened today at $21.27.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Deschner covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, ARS Pharmaceuticals, and Trevi Therapeutics. According to TipRanks, Deschner has an average return of 18.4% and a 59.26% success rate on recommended stocks.
Currently, the analyst consensus on Vera Therapeutics is a Strong Buy with an average price target of $67.36, a 216.76% upside from current levels. In a report released today, TD Cowen also reiterated a Buy rating on the stock with a $60.00 price target.
